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Background: Clostridioides difficile infection (CDI) is associated with high healthcare
demands and related costs.
Aim: To evaluate the healthcare and economic burden of CDI in hospitalized patients with
community- (HOCA-CDI) or hospital-associated CDI (HOHA-CDI) in the National Health
Service in Scotland.
Methods: A retrospective cohort study was conducted, examining data between August
2010 and July 2013 from four patient-level Scottish datasets, linked to death data. Data
examined included prior antimicrobial prescriptions in the community, hospitalizations,
length of stay and mortality. Each CDI case was matched to three hospital-based controls
on the basis of age, gender, hospital and date of admission. Descriptive economic eval-
uations were based on bed-day costs for different types of wards.
Findings: Overall, 3304 CDI cases were included in the study. CDI was associated with
additional median lengths of stay of 7.2 days for HOCA-CDI and 12.0 days for HOHA-CDI
compared with their respective, matched controls. The 30-day mortality rate was 6.8%
for HOCA-CDI and 12.4% for HOHA-CDI. Overall, recurrence within 90 days of the first CDI
episode occurred in 373/2740 (13.6%) survivors. The median additional expenditure for
each initial CDI case compared with matched controls was £1713. In the 6 months after the
index hospitalization, the cost associated with a CDI case was £5126 higher than for
controls.Microbiology Reference
Building, Glasgow Royal
G31 2ER, UK. Tel.: þ44
nhs.uk (A. Leanord).
Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article
ivecommons.org/licenses/by-nc-nd/4.0/).
C. Robertson et al. / Journal of Hospital Infection 106 (2020) 554e561 555Conclusion: Using routinely collected national data, we demonstrated the substantial
burden of CDI on healthcare services, including lengthy hospital stays and readmissions,
which increased the costs of managing patients with CDI compared with matched controls.
ª 2020 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Clostridioides difficile infection (CDI) is the most common
cause of healthcare-associated diarrhoea in developed coun-
tries and a major public health problem [1]. It is associated
with high healthcare demands and related costs, with recur-
rence of infection and the need for readmission to hospital
contributing to the burden of CDI [2]. Moreover, a recent study
estimated an excess 30-day all-cause mortality of 10.9% in
patients with CDI compared with matched patients without CDI
[3]. While CDI is mainly a hospital-associated infection, a sub-
stantial proportion of cases have onset in or association with
the community setting [4]. It is, therefore, important to
explore both hospital- and community-associated CDI to obtain
a comprehensive account of its impact on healthcare burden.
In a study from Germany, the direct treatment cost of CDI
was V18,463, compared with V14,531 for controls, with CDI
prolonging the mean overall length of stay (LOS) by 8 days [5]. A
study from Scotland found that LOS was extended by 15.8% in
patients aged 65 years with CDI compared with younger
patients aged 15e64 years with CDI [6]. Furthermore, recur-
rence of CDI appears to prolong the LOS compared with an
initial CDI episode, with some estimating a doubling of LOS [7].
Consequently, recurrent CDI substantially increases healthcare
costs [7,8]. Dubberke et al. estimated the attributable inpa-
tient cost of recurrent CDI to be US$11,631 over the 6-month
period after the initial CDI episode [9].
Owing to the considerable economic and healthcare burden
of CDI, including recurrence, an accurate assessment of asso-
ciated healthcare demands could help in the planning and
prioritization of resources.Methods
Study design and data collection
This was a cohort study, which examined linked data from
four patient-level Scottish datasets. Scotland has mandatory
reporting of CDI cases to Health Protection Scotland, with data
held on the Electronic Communication of Surveillance in Scot-
land (ECOSS) system. Healthcare encounters also have man-
datory recording of a unique patient identifier (Community
Health Index (CHI) number), enabling patient-level linkage of
data. Each CDI case from the diagnostic laboratories in Scot-
land was linked to community-based antimicrobial pre-
scriptions and hospital admissions data. Prescriptions for
antimicrobials dispensed in primary care were obtained from
the Prescribing Information System (PIS). The PIS captures 96%
of CHIs for all prescriptions dispensed in the community in
Scotland [10].
Hospital admissions data were obtained from the general/
acute and inpatient day case Scottish Morbidity Record (SMR01)dataset [11]. Mortality data were obtained from National
Records of Scotland and were linked to SMR01.
Using ECOSS data, all CDI cases aged 15 years diagnosed
during a hospital stay were identified covering the period
between 1st August 2010 and 31st July 2013. Each hospital-onset
CDI case was matched to up to three hospital-based controls,
who were hospitalized at the same time as the case, on the
basis of age (5 years), gender, hospital and date of admission
(7 days). The index date for comparisons of outcomes for the
controls was taken to be the date of diagnosis for the matched
case.
All data analysed were de-identified before being made
available to researchers for analysis in the National Safe Haven,
a secure repository for storing and sharing data for health
research. Ethics permission for this study was not required as it
used only non-identifiable routine data. Approval for the study
was granted by the National Health Service (NHS) National
Services Scotland Privacy Advisory Committee (study number
XRB14037).
Definitions
A CDI case was defined as a hospitalized patient who tested
positive for C. difficile toxin in stool concurrent with diarrhoea
not attributable to any other cause, or a patient with
C. difficile culture-positive stool concurrent with pseudo-
membranous colitis diagnosis. Cases were defined as hospital-
onset community-associated (HOCA-CDI) if the diagnostic
sample was taken 0e2 days after admission. CDI diagnosed
from samples taken from day 3 of admission was defined as
hospital-onset hospital-associated (HOHA-CDI). If a patient was
diagnosed twice with CDI within a 28-day period, the second
positive test was considered part of the same infection epi-
sode. CDI recurrence was defined as a second CDI diagnosis
28 days after the initial positive CDI test. Presumed cure of
CDI occurred for patients who had a period of 28 days after
the first positive C. difficile test with no positive result and no
death. Any result reported in the ECOSS system as equivocal
(i.e. positive for glutamate dehydrogenase but negative for
C. difficile toxin) was removed from the final dataset.
The exact date of CDI symptom onset is not systematically
reported. A proxy for the onset date of CDI from the ECOSS
system was the date that specimens were collected from
patients or, when this was unavailable, the date that speci-
mens were received by the testing laboratory or the date that
results were reported.
Assessments and statistical analyses
LOS, additional LOS owing to CDI, mortality rates for
2 months post-CDI diagnosis and the recorded cause of death
were assessed in cases and matched controls. If cases had
multiple CDI episodes, one episode was randomly selected for
August 2010–July 2013
6004 CDI episodes
identified 
5762 CDI episodes with
linked SMR
3490 CDI cases with first
episode identified as HO
2740 cases (1055 HOCA-
CDI; 1685 HOHA-CDI)
with first CDI episode
treated successfully
4002 episodes of
HOHA-CDI 
10,425 controls for
3631 CDI episodes 
One CDI episode randomly
selected for each case:
3304 cases, 9516 controls (1297
HOCA-CDI cases and 3980
controls; 2007 HOHA-CDI cases
and 5536 controls) 
One CDI episode randomly
selected for each case:
3562 cases (1310 HOCA-CDI;
2252 HOHA-CDI)
Cases not discharged from
hospital were removed (since
readmittance to hospital could
not be assessed), leaving
2338 cases
1712 cases (868 HOCA-
CDI; 844 HOHA-CDI)
discharged within
30 days of initial CDI
episode
626 cases (129 HOCA-
CDI; 497 HOHA-CDI)
discharged after
30 days of initial CDI
episode
Figure 1. Identification and selection of Clostridioides difficile infection cases and controls. CDI, Clostridioides difficile infection; HO,
hospital onset; HOCA-CDI, hospital-onset community-associated CDI; HOHA-CDI, hospital-onset hospital-associated CDI; SMR, Scottish
Morbidity Record.
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both cases and controls was analysed using a multivariable
parametric survival regression model with a log-normal dis-
tribution assumed for time to event. A robust sandwich cova-
riance matrix estimator was used to account for the matched
design. Additional LOS due to CDI was calculated by comparing
the median outcomes predicted by the survival regression
model, adjusting for deprivation, comorbidities and time in
hospital before CDI, for the cases and controls. The 95% con-
fidence intervals (CIs) for the additional LOS was obtained by
parametric bootstrapping 500 times. Patients who were
transferred to another hospital environment, ending the con-
tinuous inpatient stay, were censored at the date of transfer.
Analyses of CDI recurrence and its determinants included
cases who survived the first CDI episode (i.e. did not die or were
not censored within 28 days after the initial CDI diagnosis).
Analysis of secondary CDI recurrence included all cases who
survived at least two CDI recurrences. Multivariable competing
risks models [12,13] were used to account for mortality wheninvestigating recurrence. A sensitivity analysis was conducted
in relation to CDI recurrence, replacing 28 days with 6 and 8
weeks as the presumed date of cure.
A multivariable Cox proportional hazards survival model was
applied to investigate the determinants of hospital read-
mission. The analysis was stratified by whether the first dis-
charge was pre- or post-30 days after CDI diagnosis.
Readmission rates within 6 months after CDI diagnosis and
factors that may predict readmission were assessed in cases
who were discharged from hospital before censor/date of
death.
A multivariable Cox proportional hazards survival model was
used to compare survival between cases and matched controls.
Matched cases and controls were included as strata in the
model providing a different baseline hazard for each stratum to
account for the matched design.
In the analysis of potential risk factors, the following were
recorded: comorbidities for the index admission; comorbidities
reported in hospital admissions in the previous 5 years; number
Table I
Demographics and characteristics of Clostridioides difficile
infection cases and controls.
Variable Cases
N ¼ 3304
Controls
N ¼ 9516
Gender
Male 1385 (41.9) 3907 (41.1)
Female 1919 (58.0) 5609 (58.9)
Age group, years
15e64 807 (24.4) 2263 (23.8)
65e74 730 (22.1) 2080 (21.9)
75e84 1049 (31.8) 3159 (33.2)
85 718 (21.7) 2014 (21.2)
Origin of CDI
HOCA 1297 (39.3) e
HOHA 2007 (60.7) e
Admitted from a care home
No 3132 (94.8) 9125 (95.9)
Yes 172 (5.2) 391 (4.1)
Charlson Comorbidity Index
0 1650 (49.9) 4676 (49.1)
1 524 (15.9) 1399 (14.7)
2 600 (18.2) 1658 (17.4)
3 218 (6.6) 535 (5.6)
4 180 (5.5) 385 (4.1)
Unknown 132 (4.0) 863 (9.1)
Characteristic, median (IQR)
Antimicrobial prescriptions in
previous year
1 (0e3) 1 (0e3)
Number of admissions in
previous year
2 (1e3) 1 (0e3)
Total prescriptions in previous
year
58 (30e95) 48 (22e82)
Different prescriptions in
previous year
13 (8e18) 11 (6e16)
Length of stay (days) before
the date of CDI
5 (1e19) 4 (1e15)
Data are n (%) unless otherwise indicated.
CDI, Clostridioides difficile infection; HOCA, hospital onset
community-associated; HOHA, hospital onset hospital-associated; IQR,
interquartile range.
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microbial prescriptions in primary care, total number of pre-
scriptions (all drugs) and number of different prescriptionsTable II
Additional length of stay, in-hospital mortality and discharge from hos
HO
Cases
N ¼ 1297
Median (95% CI) additional length of stay, daysa 11.6 (7.7e18.8)
Died in hospital, N (%) 204 (15.7)
Discharged within 2 months, N (%) 966 (74.5)
CI, confidence interval; HOCA-CDI, hospital onset community-associated
associated Clostridioides difficile infection.
a Additional length of stay was adjusted according to comorbidities on ad
social deprivation.(based on approved name) dispensed in primary care in the
previous year; Charlson Comorbidity Index [14e16] based on
ICD-10 discharge codes from all hospital admissions in the
5 years prior to the CDI episode; care home residency (yes/no);
and Scottish Index of Multiple Deprivation (SIMD) quintile [17].
Cost analysis included LOS for both cases and matched
controls. The first CDI episode was selected for the cost
analysis if cases had multiple episodes. Costs were based on
daily costs for different types of beds, such as beds on a
general or critical care ward; see Supplementary Table S1.
Descriptive economic evaluations were conducted for the
NHS cost of managing the index CDI episode, the additional
cost of managing the index CDI episode compared with
matched controls, and NHS costs for hospital stay in the 6
months following the index CDI/matched control episodes.
All statistical analyses were stratified by HOHA-CDI and
HOCA-CDI. Analyses were performed using statistical software
R (version 3.2.1) [18].Results
Cases and matched controls
There were 1297 HOCA-CDI cases and 3980 matched con-
trols, and 2007 HOHA-CDI cases and 5536 matched controls.
The identification and selection of cases and controls are
shown in Figure 1. A greater number of previous hospital
admissions and prescriptions for any medications were recor-
ded in the cases, but other covariates were reasonably bal-
anced between cases and controls (Table I and Supplementary
Table S2).Outcomes
Length of stay
Adjusting for comorbidities on admission, previous admis-
sions and social deprivation, the median LOS was more than
double for CDI patients compared with controls and HOCA-CDI
cases had an additional median LOS of 7.2 days (95% CI
4.7e12.0), while HOHA-CDI cases had an additional 12.0 days
(95% CI 7.7e18.9) compared with their respective controls
(Table II).
CDI recurrence
There were 1055 HOCA-CDI and 1685 HOHA-CDI cases eligi-
ble for analysis of recurrence (Figure 1). Overall, recurrencepital according to Clostridioides difficile infection type.
CA-CDI HOHA-CDI
Controls
N ¼ 3980
Cases
N ¼ 2007
Controls
N ¼ 5536
4.4 (3.0e6.9) 22.8 (14.8e35.5) 10.8 (7.0e16.2)
211 (5.3) 527 (26.3) 644 (11.6)
3535 (88.8) 1056 (52.6) 4007 (72.4)
Clostridioides difficile infection; HOHA-CDI, hospital onset hospital-
mission, previous admissions, length of stay in hospital before CDI, and
No. events/
Total no. patients 
373/2740 85/371 108/371 1015/1712 334/626
Recurrence
≤90 days for
those who
survived first
CDI episode 
Subsequent
recurrence
≤90 days for
those who
survived first
recurrence
Subsequent
recurrence
≤1 year for
those who
survived first
recurrence
Discharged
≤30 days of
first CDI
episode and
readmitted
≤6 months
Discharged
≥30 days after
first CDI
episode and
readmitted
≤6 months  
13.6%
22.9%
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Figure 2. Recurrence of Clostridioides difficile infection and readmission to hospital for any reason. CDI, Clostridioides difficile infection.
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(13.6%) survivors (Figure 2). Recurrence rates over the 1-year
period after the initial CDI diagnosis were similar for patients
with HOCA-CDI and HOHA-CDI (Supplementary Table S3).
Recurrence occurred in 161/1055 (15.3%) HOCA-CDI cases and
212/1685 (12.6%) HOHA-CDI cases. The hazard ratio (HR, 95%
CI) for recurrence relative to patients aged 64 years was 1.51
(0.94e2.43) in patients aged 65e74 years, 1.98 (1.26e3.12) in
patients aged 75e84 years and 2.16 (1.30e3.60) in patients
aged 85 years.
After the first recurrent CDI episode, 371 cases were pre-
sumed cured. Rates of a second CDI recurrence in the next
12 months were 48/196 (24.6%) for cases with initial HOCA-CDI
and 61/175 (34.8%) for cases with initial HOHA-CDI. The sen-
sitivity analyses revealed that the recurrence rates had
little variation if replacing 28 days post-infection with 6 and
8 weeks as the presumed date of cure (Supplementary
Table S3).
Readmission to hospital
There were 868 HOCA-CDI and 844 HOHA-CDI cases that had
been discharged from hospital within 30 days of the initial CDI
episode and were eligible for analysis of readmission. Read-
mission within 6 months of the CDI episode occurred in 526/
868 (60.6%) HOCA-CDI cases and 489/844 (57.9%) HOHA-CDI
cases. The reason for readmission did not differ substantially
from the reason for index admission (Supplementary Table S4).
For patients discharged from hospital 30 days after the initial
CDI episode, 71/129 (55.0%) HOCA-CDI cases and 263/497
(52.9%) HOHA-CDI cases were readmitted to hospital within 6
months.Mortality
Within 2 months of CDI diagnosis, 15.7% of cases with
HOCA-CDI and 26.3% of cases with HOHA-CDI died in hospital,
while the corresponding rates in control patients were 5.3%
and 11.6%, respectively (Table II). The in-hospital mortality
rates and mortality rates within 2 months after CDI onset are
shown in Figure 3. The 30-day mortality rate was 6.8% for
HOCA-CDI cases and 12.4% for HOHA-CDI cases. Adjusting for
comorbidities on admission, previous hospital admissions and
social deprivation score, compared with the corresponding
controls, the HR for mortality was 2.47 (95% CI 2.04e3.00) for
HOCA-CDI cases and 2.01 (95% CI 1.79e2.25) for HOHA-CDI
cases.
Regardless of the origin of CDI, only comorbidities asso-
ciated with the current admission were positively associated
with mortality. There was no impact of social deprivation,
antimicrobial or any medication prescriptions, or the number
of hospital admissions in the 12 months prior to admission.
Admission from a care home was positively associated with
mortality (HR 1.52, 95% CI 0.94e2.45 for HOCA-CDI and HR
1.57, 95% CI 1.19e2.08 for HOHA-CDI).
Economic evaluation
The median (lower quartile (LQ), upper quartile (UQ)) index
inpatient cost was more than double for cases (£7456 (3728,
16,060)) compared with controls (£2796 (932, 8388)),
(Figure 4a). Themedian (LQ, UQ) additional cost associated with
the index inpatient stay, calculated as the difference in median
costs between cases in the index inpatient stay and matched
controls, was £1713 (-1864, 8396; Figure 4b). Median (95% CI)
longer-term costs based on all hospital stays in the 6 months
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Figure 3. Mortality by origin of Clostridioides difficile infection. CDI, Clostridioides difficile infection; HOCA-CDI, hospital onset
community-associated CDI; HOHA-CDI, hospital onset hospital-associated CDI.
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cases and £6524 (2324, 16170) for controls (Figure 4c).
Discussion
Using routinely collected national data, the present study
identified and characterized the additional burden of CDI on
the NHS in Scotland, not only in relation to patient outcome
and hospital resource use, but also its impact on hospitalization
costs. Compared with matched controls, CDI is associated with
additional median lengths of stay of 7.2 days for HOCA-CDI and
12.0 days for HOHA-CDI. The median additional expenditure for
each CDI case is £1713. In the 6 months after the index hospi-
talization, the cost associated with a CDI case is £5126 higher
than for controls. As far as we are aware, this study offers the
first European data on the economic burden of hospitalized
cases of community-associated CDI [2]. It highlights the sub-
stantial healthcare and economic burden of CDI, including
recurrent infection, and therefore provides a key rationale for
campaigns that promote the early detection and treatment of
cases and/or instigate infection control strategies to lessen the
impact of CDI. Our findings could also help service providers to
plan and prioritize resources.
From our study, patients with CDI had longer lengths of stay
and poorer outcomes than matched controls, and one in seven
patients had a second recurrence within 90 days of the initial
infection. The LOS for patients with CDI is comparable to that
in other studies based on European data [19], including a
recently published study of CDI cases over a 6-year period in
Scotland [6]. While our study did not compare the costs asso-
ciated with index CDI and recurrent CDI episodes, we calcu-
lated the costs of admissions with recurrent CDI, contributing
to the evidence that recurrent CDI adds substantially to the
total cost of treating CDI.Our study also enabled a comparison of outcomes between
community- and hospital-associated CDI, when identified in the
hospital. It has long been assumed that community-associated
CDI is less acute than hospital-associated CDI, but a substantial
proportion of patients with community-associated CDI have
serious sequelae, including severe infection, treatment fail-
ure, recurrent CDI and need for hospitalization [20,21].
Although there is a greater burden of hospital-associated dis-
ease, our study highlights that the mortality rate is similar in
hospital- and community-associated CDI groups, when the
latter is diagnosed in hospital. During the study period, w801
community-associated, community-onset CDI cases were
reported. The 30-day mortality rate of 12.4% for HOHA-CDI
cases in our study was lower than the 17.5% reported for
patients with hospital-associated CDI in a recent study from
Scotland, although a greater proportion of patients in this
other study had a higher Charlson Comorbidity Index compared
with our study [6].
While a recently published study also reported on the
impact of CDI on LOS and mortality in patients in Scotland [6],
no data on costs, recurrent infection or readmissions were
included. The present study considers the current economic
burden in the NHS in the United Kingdom and highlights the
substantial cost associated with the acute management of CDI.
We demonstrate that the burden of financial cost continues
over an extended period of time, such that 6 months after the
acute episode there is still a clear and significant difference in
cost between cases and controls. Recent data from both 2016/
17 and 2017/18 suggest that 31% of all patients admitted to
hospital have more than one admission within a year [22,23]; in
our study, 57.7% of all hospital-onset CDI patients, from an
earlier period (2010e2013), were readmitted within 6 months,
suggesting that hospital-onset CDI is associated with partic-
ularly high rates of hospital readmission.
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Figure 4. Economic evaluation of Clostridioides difficile infection
(CDI) cases and controls in relation to (a) costs associated with
first continuous inpatient stay after CDI diagnosis, (b) additional
costs of cases versus controls for first continuous inpatient stay,
and (c) longer term costs in the 6 months after CDI diagnosis. For
(a), all costs valued above £40,000 were revalued as £40,000,
while for (b) and (c), all costs valued above £60,000 were revalued
as £60,000.
C. Robertson et al. / Journal of Hospital Infection 106 (2020) 554e561560A key strength of this study was the matched design for
estimating costs. The study design also minimized the impact
of bias and confounding factors on our analyses. As a limitation,
we recognize that the quality of the retrospective data relies
on the accuracy and completeness of the medical records,
although it is presumed that cases and controls were subject to
the same issues. Additionally, and unlike the definition pro-
vided by the European Centre for Disease Prevention and
Control (ECDC), our definition of HOCA-CDI did not take into
account previous hospital discharges 4 weeks of the current
admission [24], and therefore some HOCA-CDI cases may have
been healthcare-associated CDI. Likewise, our definition of
recurrent CDI incorporated a different timeline (second CDI
diagnosis 28 days after the initial positive CDI test) than that
from the ECDC (second CDI >2 weeks and <8 weeks after onset
of previous episode) [24]. Consequently, the current study may
have under- or over-estimated HOCA-CDI and recurrent CDI.
Also, the prescribing data used in our study were derived from
primary care, rather than prescriptions received during the
hospital stay. Furthermore, our analysis did not include cost
data associated with prescribing or management within the
community. Finally, by selecting the first CDI episode within
the time period for individuals with multiple CDI episodes, we
estimated the total additional costs of CDI within 6 months,
which may have resulted in an overestimate compared with the
selection of an episode at random, as had been done for the
estimation of recurrence and readmission rates.
In conclusion, CDI poses a substantial burden on healthcare
services, including lengthy hospital stays, and after the infec-
tion, patients are at greater risk of readmission to hospital,
even for non-CDI reasons. Consequently, there are increased
costs associated with the management of patients with CDI
compared with matched controls.Acknowledgements
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